Factor Xa inhibitors.
Walenga
Jeanine M
JM
Department of Thoracic-Cardiovascular Surgery, Cardiovascular Institute, Loyola University Medical Center, Maywood, IL, USA.
Jeske
Walter P
WP
Hoppensteadt
Debra
D
Fareed
Jawed
J
D000818:Animals; D000925:Anticoagulants / Q000145:classification / Q000494:pharmacology; D065427:Factor Xa Inhibitors; D006493:Heparin / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D007447:Invertebrate Hormones / Q000494:pharmacology; D008074:Lipoproteins / Q000494:pharmacology; D009281:Naphthalenes / Q000494:pharmacology; D009844:Oligosaccharides / Q000494:pharmacology; D011422:Propionates / Q000494:pharmacology; D012008:Recurrence; D013927:Thrombosis / Q000188:drug therapy
C086910:(2S)-2-(4-(((3S)-1-acetimidoyl-3-pyrrolidinyl)oxy)phenyl)-3-(7-amidino-2-naphtyl)propanoic acid; D000925:Anticoagulants; D065427:Factor Xa Inhibitors; D007447:Invertebrate Hormones; D008074:Lipoproteins; D009281:Naphthalenes; D009844:Oligosaccharides; D011422:Propionates; C051928:lipoprotein-associated coagulation inhibitor; C053155:antistasin; C049714:IC 831423; D006493:Heparin